WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Whitehawk Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.01+0.12 (+4.15%)
Close on Oct 19, 2026
- Market cap
- $249.49M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
75.8%
43M of 57M shares
Institutional holders
78
29 new, 12 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 14 sales
Net sold $2.58M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fan Yu | 5,679,253 | 9.40% | 13G (passive) amendment | Jun 30, 2026 |
| Anupam Dalal | 4,843,775 | 9.00% | 13D (active) amendment | May 14, 2026 |
| Suvretta Capital Management, LLC | 4,727,510 | 9.99% | 13G (passive) | Mar 4, 2025 |
| OrbiMed Genesis GP LLC | 4,166,000 | 8.90% | 13G (passive) | Mar 31, 2025 |
| OrbiMed Advisors LLC | 3,934,296 | 7.30% | 13G (passive) amendment | Jun 30, 2026 |
| Coastlands Capital LLC | 2,819,215 | 5.98% | 13G (passive) | Aug 19, 2025 |
| QVT Financial LP | 2,313,702 | 9.37% | 13G (passive) | Dec 31, 2024 |
| Behzad Aghazadeh | 18,292,675 | 19.99% | 13D (active) amendment | May 12, 2026 |
| Point72 Capital Advisors, Inc. | 1,470,311 | 6.00% | 13G (passive) | Jan 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of WHWK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Yu Fan | 4,861,314 | 8.53% | $22.26M | +2,791,314 | 20.63% |
| Acuta Capital Partners, LLC | 4,685,912 | 8.22% | $21.46M | +1,275,510 | 14.96% |
| QVT Financial LP | 4,615,709 | 8.10% | $21.14M | – | 1.27% |
| Suvretta Capital Management, LLC | 4,300,000 | 7.54% | $19.69M | +600,000 | 0.36% |
| Orbimed Advisors LLC | 3,934,296 | 6.90% | $18.02M | −231,704 | 0.33% |
| Avoro Capital Advisors LLC | 2,849,402 | 5.00% | $13.05M | – | 0.12% |
| Siren, L.L.C. | 2,337,102 | 4.10% | $10.70M | +255,102 | 0.22% |
| KVP Capital Advisors, LP | 2,165,997 | 3.80% | $9.92M | – | 7.28% |
| BlackRock, Inc. | 1,922,828 | 3.37% | $8.81M | +1,571,443 | 0.00% |
| Vanguard Capital Management LLC | 1,388,561 | 2.44% | $6.36M | +72,791 | 0.00% |
| ADAR1 Capital Management, LLC | 1,341,394 | 2.35% | $6.14M | +1,212,891 | 0.28% |
| Acorn Capital Advisors, LLC | 1,139,363 | 2.00% | $5.22M | – | 1.42% |
| Stempoint Capital LP | 1,021,037 | 1.79% | $4.68M | −857,701 | 0.81% |
| Geode Capital Management, LLC | 899,780 | 1.58% | $4.12M | +442,240 | 0.00% |
| Ally Bridge Group (NY) LLC | 817,939 | 1.43% | $3.75M | – | 3.31% |
| Woodline Partners LP | 436,614 | 0.77% | $2.00M | +155,117 | 0.01% |
| Renaissance Technologies LLC | 413,822 | 0.73% | $1.90M | −14,800 | 0.00% |
| State Street Corp | 386,982 | 0.68% | $1.77M | +226,600 | 0.00% |
| Millennium Management LLC | 380,406 | 0.67% | $1.74M | +70,732 | 0.00% |
| Eversept Partners, LP | 303,306 | 0.53% | $1.39M | −3,494 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 78 | 43M | 75.8% | 29 / 29 | 11 / 12 | 10M | 2M |
| Q1 2026 | 62 | 35M | 61.7% | 21 / 16 | 7 / 6 | 4M | 0M |
| Q4 2025 | 48 | 33M | 57.8% | 12 / 10 | 6 / 5 | 5M | 1M |
| Q3 2025 | 41 | 29M | 50.6% | 5 / 6 | 10 / 3 | 1M | 1M |
| Q2 2025 | 39 | 29M | 51.6% | 2 / 9 | 11 / 13 | 1M | 3M |
| Q1 2025 | 50 | 32M | 55.8% | 9 / 13 | 16 / 11 | 18M | 1M |
| Q4 2024 | 53 | 15M | 26.3% | 8 / 12 | 16 / 7 | 5M | 2M |
| Q3 2024 | 52 | 12M | 21.0% | 10 / 7 | 22 / 22 | 4M | 4M |
| Q2 2024 | 65 | 11M | 20.1% | 21 / 14 | 22 / 16 | 1M | 4M |
| Q1 2024 | 60 | 14M | 24.8% | 9 / 18 | 16 / 13 | 2M | 1M |
| Q4 2023 | 65 | 13M | 23.3% | 12 / 26 | 11 / 19 | 2M | 3M |
| Q3 2023 | 73 | 15M | 25.8% | 12 / 25 | 15 / 6 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of WHWK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 887,972 | 1.56% | $4.07M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 734,137 | 1.29% | $3.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 470,854 | 0.83% | $2.16M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 352,173 | 0.62% | $1.36M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 281,712 | 0.49% | $1.29M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 192,391 | 0.34% | $908.09K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 165,284 | 0.29% | $757.00K | 0.77% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 110,575 | 0.19% | $506.43K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 78,832 | 0.14% | $303.50K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 62,161 | 0.11% | $293.40K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 60,657 | 0.11% | $277.81K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 57,711 | 0.10% | $272.40K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 46,572 | 0.08% | $219.82K | 0.00% | May 31, 2026 |
| Fidelity Small Cap Value Index Fund | 45,075 | 0.08% | $206.44K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 43,799 | 0.08% | $168.63K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David James Lennon | CHIEF EXECUTIVE OFFICER, Director | 569,643 | 1.00% | Sep 18, 2026 |
| David Dornan | Chief Scientific Officer | – | – | Sep 18, 2026 |
| Scott M. Giacobello | CHIEF FINANCIAL OFFICER | 333,489 | 0.58% | Sep 18, 2026 |
| Margaret Dugan | Chief Medical Officer | 19,132 | 0.03% | Sep 18, 2026 |
| Bryan Ball | See remarks | 448,126 | 0.79% | Sep 18, 2026 |
| Vijay K. Iyengar | Director | – | – | Sep 11, 2026 |
| Anupam Dalal | Director | 4,687,042 | 8.22% | Jul 30, 2026 |
| Behzad Aghazadeh | Director, 10% owner | 2,211,752 | 3.88% | Jun 15, 2026 |
| Capital Advisors LLC Avoro | Director, 10% owner | – | – | Jun 15, 2026 |
| Ventures LLC Avoro | Director, 10% owner | 3,471,752 | 6.09% | Jun 15, 2026 |
| Richard E. Maroun | Director | – | – | Jun 15, 2026 |
| Caley Castelein | Director | 2,440,794 | 4.28% | Jun 15, 2026 |
| Emma Reeve | Director | – | – | Jun 15, 2026 |
| Neil Desai | Director | 1,171,543 | 2.06% | Jun 15, 2026 |
| Mohammad Hirmand | Director | – | – | Jun 15, 2026 |
| Baiteng Zhao | Director | 1,250,000 | 2.19% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Anupam Dalal Director | May 14, 2026 | Award | +1,275,510 | $3.92 | $5.00M | 4,685,912 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | May 14, 2026 | Award | +51,021 | $3.92 | $200.00K | 569,643 |
| Margaret Dugan Chief Medical Officer | May 14, 2026 | Award | +19,132 | $3.92 | $75.00K | 19,132 |
| Bryan Ball See remarks | May 14, 2026 | Award | +51,020 | $3.92 | $200.00K | 448,126 |
| Caley Castelein Director | May 14, 2026 | Award | +255,102 | $3.92 | $1,000.00K | 274,796 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | May 14, 2026 | Award | +38,265 | $3.92 | $150.00K | 333,489 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 16, 2026 | Sale | −141,600 | $4.13 | $584.81K | 295,224 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 15, 2026 | Sale | −77,000 | $3.86 | $297.22K | 436,824 |
| Bryan Ball See remarks | Apr 14, 2026 | Sale | −92,460 | $3.64 | $336.55K | 397,106 |
| Bryan Ball See remarks | Apr 13, 2026 | Sale | −26,389 | $3.46 | $91.31K | 489,566 |
| Bryan Ball See remarks | Apr 10, 2026 | Sale | −6,596 | $3.43 | $22.62K | 515,955 |
| Bryan Ball See remarks | Apr 9, 2026 | Sale | −50,000 | $3.57 | $178.50K | 522,551 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 9, 2026 | Sale | −14,500 | $3.38 | $49.01K | 518,622 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 8, 2026 | Sale | −63,945 | $3.40 | $217.41K | 533,122 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 7, 2026 | Sale | −94,087 | $3.43 | $322.72K | 597,067 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 6, 2026 | Sale | −102,395 | $3.51 | $359.41K | 691,154 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 2, 2026 | Sale | −26,858 | $3.48 | $93.47K | 793,549 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Apr 1, 2026 | Option exercise | +775,828 | – | – | 820,407 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Apr 1, 2026 | Option exercise | +473,902 | – | – | 502,002 |
| Bryan Ball See remarks | Apr 1, 2026 | Option exercise | +366,532 | – | – | 572,551 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 2, 2026 | Sale | −2,594 | $3.31 | $8.59K | 28,100 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Sale | −5,100 | $3.31 | $16.88K | 44,579 |
| Bryan Ball See remarks | Mar 2, 2026 | Sale | −1,834 | $3.31 | $6.07K | 206,019 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 1, 2026 | Option exercise | +6,750 | – | – | 30,694 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2026 | Option exercise | +16,250 | – | – | 49,679 |
| Bryan Ball See remarks | Mar 1, 2026 | Option exercise | +5,000 | – | – | 207,853 |
| Anupam Dalal Director | Mar 4, 2025 | Award | +1,561,000 | $2.40 | $3.75M | 3,410,402 |
| Bryan Ball See remarks | Mar 4, 2025 | Award | +100,000 | $2.40 | $240.00K | 202,853 |
| Caley Castelein Director | Mar 4, 2025 | Award | +1,666,000 | $2.40 | $4.00M | 2,165,998 |
| Baiteng Zhao Director | Mar 4, 2025 | Award | +1,250,000 | $2.40 | $3.00M | 1,250,000 |
| Bryan Ball See remarks | Mar 3, 2025 | Sale | −2,147 | $2.35 | $5.05K | 102,853 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 3, 2025 | Sale | −2,806 | $2.35 | $6.59K | 23,944 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 3, 2025 | Sale | −5,690 | $2.35 | $13.37K | 33,429 |
| Bryan Ball See remarks | Mar 1, 2025 | Option exercise | +5,000 | – | – | 105,000 |
| Scott M. Giacobello CHIEF FINANCIAL OFFICER | Mar 1, 2025 | Option exercise | +6,750 | – | – | 26,750 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Mar 1, 2025 | Option exercise | +16,250 | – | – | 39,119 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Oct 3, 2024 | Sale | −9,689 | $1.94 | $18.80K | 22,869 |
| David James Lennon CHIEF EXECUTIVE OFFICER, Director | Oct 2, 2024 | Option exercise | +32,558 | – | – | 32,558 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Sep 3, 2024 | Sale(10b5-1 plan) | −40,000 | $1.71 | $68.40K | 1,171,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 5, 2024 | Sale(10b5-1 plan) | −5,652 | $1.34 | $7.57K | 1,211,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 2, 2024 | Sale(10b5-1 plan) | −18,933 | $1.41 | $26.70K | 1,217,195 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Aug 1, 2024 | Sale(10b5-1 plan) | −15,415 | $1.50 | $23.12K | 1,236,128 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jul 2, 2024 | Sale(10b5-1 plan) | −8,652 | $1.34 | $11.59K | 1,251,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jul 1, 2024 | Sale(10b5-1 plan) | −31,348 | $1.45 | $45.45K | 1,260,195 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −20,225 | $1.77 | $35.80K | 1,291,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Jun 3, 2024 | Sale(10b5-1 plan) | −19,775 | $1.81 | $35.79K | 1,311,768 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | May 1, 2024 | Sale(10b5-1 plan) | −40,000 | $1.93 | $77.20K | 1,331,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Apr 2, 2024 | Sale(10b5-1 plan) | −22,228 | $2.23 | $49.57K | 1,371,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Apr 1, 2024 | Sale(10b5-1 plan) | −17,772 | $2.31 | $41.05K | 1,393,771 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Mar 4, 2024 | Sale(10b5-1 plan) | −14,964 | $2.10 | $31.42K | 1,411,543 |
| Neil Desai EXECUTIVE CHAIRMAN, Director | Mar 1, 2024 | Sale(10b5-1 plan) | −27,036 | $1.97 | $53.26K | 1,426,507 |
| Neil Desai Executive Chairman, Director | Feb 1, 2024 | Sale(10b5-1 plan) | −42,000 | $1.74 | $73.08K | 1,453,543 |
| Neil Desai Executive Chairman, Director | Jan 2, 2024 | Sale(10b5-1 plan) | −42,000 | $2.06 | $86.52K | 1,495,543 |
| Neil Desai Executive Chairman, Director | Dec 6, 2023 | Sale(10b5-1 plan) | −7,037 | $4.82 | $33.92K | 1,537,543 |
| Neil Desai Executive Chairman, Director | Dec 5, 2023 | Sale(10b5-1 plan) | −15,740 | $5.02 | $79.01K | 1,544,580 |
| Neil Desai Executive Chairman, Director | Dec 4, 2023 | Sale(10b5-1 plan) | −10,876 | $5.15 | $56.01K | 1,560,320 |
| Neil Desai Executive Chairman, Director | Dec 1, 2023 | Sale(10b5-1 plan) | −8,347 | $5.14 | $42.90K | 1,571,196 |
| Neil Desai Executive Chairman, Director | Nov 2, 2023 | Sale(10b5-1 plan) | −31,662 | $4.46 | $141.21K | 1,579,543 |
| Neil Desai Executive Chairman, Director | Nov 1, 2023 | Sale(10b5-1 plan) | −10,338 | $4.32 | $44.66K | 1,611,205 |
| Neil Desai Executive Chairman, Director | Oct 3, 2023 | Sale(10b5-1 plan) | −16,431 | $4.10 | $67.37K | 1,621,543 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Scott M. Giacobello Officer | Apr 15, 2026 | 233,766 | $900.00K | Apr 15, 2026 | Restricted Stock Units |
| David James Lennon Officer, Director | Apr 9, 2026 | 4,364 | $14.75K | Apr 9, 2026 | Restricted Stock Units |
| Bryan Ball Officer | Apr 9, 2026 | 196,969 | $650.00K | Apr 9, 2026 | Restricted Stock Units |
| David James Lennon Officer, Director | Apr 2, 2026 | 297,421 | $1.03M | Apr 2, 2026 | Restricted Stock Units |
| Scott M. Giacobello Officer | Mar 3, 2025 | 2,806 | $6.59K | Mar 3, 2025 | Restricted Stock Units |
| David James Lennon Officer, Director | Mar 3, 2025 | 5,690 | $13.37K | Mar 3, 2025 | Restricted Stock Units |
| Bryan Ball Officer | Mar 3, 2025 | 2,147 | $5.05K | Mar 3, 2025 | Restricted Stock Units |
| David James Lennon Officer, Director | Oct 3, 2024 | 9,689 | $18.80K | Oct 3, 2024 | Restricted Stock Units |
| Neil Desai Officer | Sep 3, 2024 | 120,000 | $214.42K | Sep 3, 2024 | Share Conversion |
| Neil Desai Officer | Jun 3, 2024 | 120,000 | $220.00K | Jun 3, 2024 | Share Conversion |
| Neil Desai Officer | Mar 1, 2024 | 122,000 | $241.12K | Mar 1, 2024 | Share Conversion |
| Neil Desai Officer | Dec 1, 2023 | 126,000 | $668.43K | Dec 1, 2023 | Share Conversion |
| Neil Desai Officer | Sep 1, 2023 | 126,000 | $787.68K | Sep 1, 2023 | Share Conversion |
| Neil Desai Officer | Jul 3, 2023 | 84,000 | $574.56K | Jul 3, 2023 | Share Conversion |
| Neil Desai Officer | Apr 3, 2023 | 126,000 | $932.72K | Apr 3, 2023 | Share Conversion |